Burcher, K., Feng, A., Coring, T., Addis, T., Sellars, E., Martin, M., … Kang, Y. (2025). Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma. In Blood (Vol. 146, pp. 6379–6379). American Society of Hematology. https://doi.org/10.1182/blood-2025-6379

Burcher, Kimberly, Amber Feng, Terrell Coring, Taylor Addis, Emily Sellars, Melissa Martin, Tanya Bellavia, et al. “Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma.” In Blood, 146:6379–6379. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-6379.

Burcher K, Feng A, Coring T, Addis T, Sellars E, Martin M, et al. Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma. In: Blood. American Society of Hematology; 2025. p. 6379–6379.

Burcher, Kimberly, et al. “Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 6379–6379. Crossref, doi:10.1182/blood-2025-6379.

Burcher K, Feng A, Coring T, Addis T, Sellars E, Martin M, Bellavia T, Jones L, Schrum D, Eberwein E, Kennedy E, Gasparetto C, Costa Chase C, Choi T, Ramalingam S, Long G, Kirby S, Lin C, Kang Y. Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma. Blood. American Society of Hematology; 2025. p. 6379–6379.